These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37967490)

  • 1. The Checklist for Standard Methodological Requirements and Reporting of Economic Evaluation of Medicines in Slovakia.
    Bucek Psenkova M; Hlavinkova L; Visnansky M; Grega D; Ondrusova M
    Value Health Reg Issues; 2024 Jan; 39():14-19. PubMed ID: 37967490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
    Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
    Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA.
    Tesar T; Hloska A; Wawruch M; Lehocka L; Snopkova M; Masarykova L
    Int J Technol Assess Health Care; 2017 Jan; 33(3):345-349. PubMed ID: 28434416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology.
    Inotai A; Pékli M; Jóna G; Nagy O; Remák E; Kaló Z
    BMC Health Serv Res; 2012 Sep; 12():332. PubMed ID: 22999574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Cost-Savings From the Use of the Biosimilars in Slovakia.
    Tesar T; Golias P; Kobliskova Z; Wawruch M; Kawalec P; Inotai A
    Front Public Health; 2020; 8():431. PubMed ID: 32974261
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug Policy in Slovakia.
    Bucek Psenkova M; Visnansky M; Mackovicova S; Tomek D
    Value Health Reg Issues; 2017 Sep; 13():44-49. PubMed ID: 29073987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia.
    Tesar T; Obsitnik B; Kaló Z; Kristensen FB
    Front Pharmacol; 2019; 10():664. PubMed ID: 31249529
    [No Abstract]   [Full Text] [Related]  

  • 8. Consolidated Health Economic Evaluation Reporting Standards - Value of Information (CHEERS-VOI): Explanation and Elaboration.
    Kunst N; Siu A; Drummond M; Grimm SE; Grutters J; Husereau D; Koffijberg H; Rothery C; Wilson ECF; Heath A
    Value Health; 2023 Oct; 26(10):1461-1473. PubMed ID: 37414276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia.
    Tesar T; Golias P; Masarykova L; Kawalec P; Inotai A
    Front Pharmacol; 2021; 12():795002. PubMed ID: 34966285
    [No Abstract]   [Full Text] [Related]  

  • 11. Reporting Quality of Discrete Event Simulations in Healthcare-Results From a Generic Reporting Checklist.
    Zhang X; Lhachimi SK; Rogowski WH
    Value Health; 2020 Apr; 23(4):506-514. PubMed ID: 32327168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines.
    Ramaekers BL; Joore MA; Grutters JP
    Value Health; 2013; 16(5):855-62. PubMed ID: 23947981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement.
    Gates M; Gates A; Pieper D; Fernandes RM; Tricco AC; Moher D; Brennan SE; Li T; Pollock M; Lunny C; Sepúlveda D; McKenzie JE; Scott SD; Robinson KA; Matthias K; Bougioukas KI; Fusar-Poli P; Whiting P; Moss SJ; Hartling L
    BMJ; 2022 Aug; 378():e070849. PubMed ID: 35944924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review and Quality Evaluation of Pharmacoeconomic Studies on Traditional Chinese Medicines.
    Yang N; Zhang H; Deng T; Guo JJ; Hu M
    Front Public Health; 2021; 9():706366. PubMed ID: 34414159
    [No Abstract]   [Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
    Philips Z; Ginnelly L; Sculpher M; Claxton K; Golder S; Riemsma R; Woolacoot N; Glanville J
    Health Technol Assess; 2004 Sep; 8(36):iii-iv, ix-xi, 1-158. PubMed ID: 15361314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.
    Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
    BMJ; 2013 Mar; 346():f1049. PubMed ID: 23529982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of QA and QC standards in radiology in Slovakia.
    Nikodemová D; Horváthová M; Salát D
    Radiat Prot Dosimetry; 2005; 117(1-3):274-6. PubMed ID: 16461525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review.
    Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR
    Ther Adv Drug Saf; 2023; 14():20420986221143272. PubMed ID: 36713000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.